PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice

Journal of Pharmaceutical Sciences

Volumn 104, Issue 5, 2015, Pages 1848-1855

  Landersdorfer, Cornelia B ^a   Caliph, Suzanne M ^a   Shackleford, David M ^a   Ascher, David B ^b   Kaminskas, Lisa M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Absorption; Bioavailability; Elimination; Gender; Macromolecular drug delivery; Mathematical model; Pegylation; Pharmacokinetics; Population pharmacokinetics

Indexed keywords

PEGINTERFERON ALPHA2B; INTERFERON; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; ELIMINATION HALF-LIFE; FEMALE; IMMUNE STATUS; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; NUDE MOUSE; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; BIOAVAILABILITY; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECTS; IMMUNOCOMPETENCE; METABOLIC CLEARANCE RATE; PHYSIOLOGY; SEXUAL DEVELOPMENT;

ANIMALS; BIOLOGICAL AVAILABILITY; FEMALE; IMMUNOCOMPETENCE; INTERFERONS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MICE, NUDE; POLYETHYLENE GLYCOLS; SEX CHARACTERISTICS;

EID: 84926656059     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24412     Document Type: Article

References (35)

1. Regitz-Zagrosek V, Seeland U. 2012. Sex and gender differences in clinical medicine. Handb Exp Pharmacol 214:3-22.
2. Schiebinger L. 2014. Scientific research must take gender into account. Nature 507:9.
3. Caliph SM, Shackleford D, Ascher DB, Kaminskas LM. 2015. Practical lessons in murine thoracic lymph duct cannulations: Observations in female and male mice across four different strains that impact on 'cannulatability'. J Pharm Sci 104(3):1207-1209.
4. Makhmudov ZA. 1980. [Sex characteristics of the anatomy of the superior mesenteric lymph nodes in an adult]. Arkh Anat Gistol Embriol 79:63-66.
5. Richter WF, Bhansali SG, Morris ME. 2012. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14:559-570.
6. La-Beck NM, Wu H, Infante JR, Jones SF, Burris HA, Keedy VL, Kodaira H, Ikeda S, Ramanathan RK, Zamboni W. 2010. The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents. J Clin Oncol 28:e13003.
7. Sapino A, Cassoni P, Ferrero E, Bongiovanni M, Righi L, Fortunati N, Crafa P, Chiarle R, Bussolati G. 2003. Estrogen receptor alpha is a novel marker expressed by follicular dendritic cells in lymph nodes and tumor-associated lymphoid infiltrates. Am J Pathol 163:1313-1320.
8. Maeda H. 2012. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 164:138-144.
9. Vaessen LMB, Broekhuizen R, Rozing J, Vos JG, Schuurman HJ. 1986. T-cell development during aging in congenitally athymic (nude) rats. Scand J Immunol 24:223-235.
10. Kaminskas LM, Kelly BD, McLeod VM, Boyd BJ, Krippner GY, Williams ED, Porter CJ. 2009. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol Pharm 6:1190-1204.
11. Mamede M, Saga T, Ishimori T, Nakamoto Y, Sato N, Higashi T, Mukai T, Kobayashi H, Konishi J. 2003. Differential uptake of (18)F-fluorodeoxyglucose by experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of immunomodification. Neoplasia 5:179-183.
12. Gupta S, Jen J, Kolz K, Cutler D. 2007. Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 63:292-299.
13. Xu C, Gupta S, Krishna G, Cutler D, Wirth S, Galoppo C, Ciocca M, Kolz K, Noviello S, Sniukiene V. 2013. Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. Eur J Clin Pharmacol 69:2045-2054.
14. Villa E, Camma C, Di Leo A, Karampatou A, Enea M, Gitto S, Bernabucci V, Losi L, De Maria N, Lei B, Ferrari A, Vukotic R, Vignoli P, Rendina M, Francavilla A. 2012. Peginterferon-alpha-2B plus ribavirin is more effective than peginterferon-alpha-2A plus ribavirin in menopausal women with chronic hepatitis C. J Viral Hepat 19:640-649.
15. Kaminskas LM, Ascher DB, McLeod VM, Herold MJ, Le CP, Sloan EK, Porter CJH. 2013. PEGylation of interferon alpha2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. J Control Release 168:200-208.
16. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 13:201-211.
17. Bulitta JB, Landersdorfer CB. 2011. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J 13:212-226.
18. Bulitta JB, Landersdorfer CB, Forrest A, Brown SV, Neely MN, Tsuji BT, Louie A. 2011. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol 12:2044-2061.
19. Neely MN, Rakhmanina NY. 2011. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin Pharm 50:143-189.
20. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL, International Society of Anti-Infective P, the P, Pharmacodynamics Study Group of the European Society of Clinical M, Infectious D. 2014. Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions. Lancet Infect Dis 14:498-509.
21. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. 1999. The type I interferon receptor: Structure, function, and evolution of a family business. J Interferon Cytokine Res 19:1069-1098.
22. de Weerd NA, Nguyen T. 2012. The interferons and their receptors - Distribution and regulation. Immunol Cell Biol 90:483-491.
23. Mager DE, Jusko WJ. 2002. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharm Res 19:1537-1543.
24. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. 2003. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther 306:262-270.
25. Mager DE, Neuteboom B, Jusko WJ. 2005. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res 22:58-61.
26. Riggs MM, Bergsma TT, Rogers JA, Gastonguay MR, Subramanian GM, Chen C, Devalaraja M, Corey AE, Sun H, Yu J, Stein DS. 2012. Population pharmacokinetics and exposure-response of albinterferon alfa-2b. J Clin Pharmacol 52:475-486.
27. Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, Masur H, Dewar RL, Ferenci P, Silva M, Viola MS, Polis MA, Kottilil S. 2009. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS 23:2439-2450.
28. Kaminskas LM, Ascher DB, McLeod VM, Herold MJ, Le CP, Sloan EK, Porter CJ. 2013. PEGylation of interferon alpha2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. J Control Release 168:200-208.
29. Ahn J, Flamm S. 2004. Peginterferon-alpha(2b) and ribavirin. Expert Rev Anti Infect Ther 2:17-25.
30. PEG-Intron prescribing information. Accessed on December 22, 2014, at: http://www.pegintron.com/peg/pegintron/consumer/index.jsp.
31. Malaponte G, Passero E, Leonardi S, Monte V, Lauria C, Mazzarino C, Sciotto A, Russo Mancuso G, Di Gregorio F, Musumeci S. 1997. Effect of alpha-interferon on natural killer cell activity and lymphocyte subsets in thalassemia patients with chronic hepatitis C. Acta Haematol 98:83-88.
32. Ikeda H, Old LJ, Schreiber RD. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95-109.
33. Mirrashed F, Sharp JC, Krause V, Morgan J, Tomanek B. 2004. Pilot study of dermal and subcutaneous fat structures by MRI in individuals who differ in gender, BMI, and cellulite grading. Skin Res Technol 10:161-168.
34. Unno N, Tanaka H, Suzuki M, Yamamoto N, Mano Y, Sano M, Saito T, Konno H. 2011. Influence of age and gender on human lymphatic pumping pressure in the leg. Lymphol 44:113-120.
35. Shvetsov EV. 1991. [Anatomy and topography of external iliac lymph nodes in adults]. Arkh Anat Gistol Embriol 100:50-57.